Peripheral CX3CR1⁺ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer

References

• Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–14. doi:10.1016/S0140-6736(16)30958-8.
   PubMed Web of Science ®Google Scholar
• Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. doi:10.1186/s12943-023-01740-y.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Katiyar V, Chesney J, Kloecker G. Cellular therapy for lung cancer: focusing on Chimeric Antigen Receptor T (CAR T) cells and Tumor-Infiltrating Lymphocyte (TIL) therapy. Cancers Basel. 2023;15(14):15(14. doi:10.3390/cancers15143733.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K, Matsui T, Sugita Y, Takahashi Y, Nishida R. et al. Single-cell sequencing on CD8+TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer. J Immunother Cancer. 2023;11(8). doi:10.1136/jitc-2023-007180.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS. et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med. 2013;369(2):134–144. doi:10.1056/NEJMoa1305133.
   PubMed Web of Science ®Google Scholar
• Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, Chaput N, Duchemann B. Adoptive cell therapies in thoracic malignancies. Cancer Immunol Immunother. 2022;71(9):2077–2098. doi:10.1007/s00262-022-03142-3.
   PubMed Web of Science ®Google Scholar
• Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, Zhang Y, Corse E, Hu Y, Han W. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022;3(1):108–121. doi:10.1038/s43018-021-00292-8.
   PubMedGoogle Scholar
• Zhang Z, Zhang C, Luo Y, Wu P, Zhang G, Zeng Q, Wang L, Yang Z, Xue L, Zheng B. et al. m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med. 2021;19(1):284. doi:10.1186/s12916-021-02148-5.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM. et al. T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–2262. doi:10.1056/NEJMoa1609279.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y-C, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730. doi:10.1038/s41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410–1418. doi:10.1038/s41591-021-01462-y.
   PubMed Web of Science ®Google Scholar
• Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947–953. doi:10.1038/s41591-019-0421-7.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733. doi:10.1056/NEJMoa1103849.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D. et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26):2545–2554. doi:10.1056/NEJMoa1708566.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM. et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640–654. doi:10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S. et al. Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 2018;24(16):3981–3993. doi:10.1158/1078-0432.CCR-17-1788.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, Lei Y, Huang Y. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer. 2022;13(7):889–899. doi:10.1111/1759-7714.14375.
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–2560. doi:10.7150/ijbs.34213.
   PubMed Web of Science ®Google Scholar
• Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS. Chimeric Antigen Receptor (CAR) T-Cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16–26. doi:10.1016/j.jtho.2017.10.001.
   PubMed Web of Science ®Google Scholar
• Martinez M, Moon EK. CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128. doi:10.3389/fimmu.2019.00128.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–438. doi:10.1038/nm.4051.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981–3991. doi:10.1172/JCI82416.
   PubMed Web of Science ®Google Scholar
• Bräunlein E, Lupoli G, Füchsl F, Abualrous ET, de Andrade Krätzig N, Gosmann D, Wietbrock L, Lange S, Engleitner T, Lan H. et al. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. J Immunother Cancer. 2021;9(9):e002754. doi:10.1136/jitc-2021-002754.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME. et al. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J Exp Med. 2021;218(4). doi:10.1084/jem.20200920.
   PubMed Web of Science ®Google Scholar
• Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, Garg R, de la Torre JC, von Andrian UH. The chemokine receptor CX3CR1 defines three antigen-experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis. Immunity. 2016;45(6):1270–1284. doi:10.1016/j.immuni.2016.10.018.
   PubMed Web of Science ®Google Scholar
• Trinh T, Adams WA, Calescibetta A, Tu N, Dalton R, So T, Wei M, Ward G, Kostenko E, Christiansen S. et al. CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience. 2023;26(4):106443. doi:10.1016/j.isci.2023.106443.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I. et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):1402. doi:10.1038/s41467-021-21619-0.
   PubMed Web of Science ®Google Scholar
• Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25(1):89–94. doi:10.1038/s41591-018-0266-5.
   PubMed Web of Science ®Google Scholar
• Al-Habsi M, Chamoto K, Matsumoto K, Nomura N, Zhang B, Sugiura Y, Sonomura K, Maharani A, Nakajima Y, Wu Y. et al. Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice. Science. 2022;378(6618):eabj3510. doi:10.1126/science.abj3510.
   PubMed Web of Science ®Google Scholar
• Wang B, Chen Z, Huang Y, Ding J, Lin Y, Wang M, Li X. Mitochondrial mass of circulating NK cells as a novel biomarker in severe SARS-CoV-2 infection. Int Immunopharmacol. 2023;124(Pt A):110839. doi:10.1016/j.intimp.2023.110839.
   PubMedGoogle Scholar
• Sukumar M, Liu J, Mehta G, Patel S, Roychoudhuri R, Crompton J, Klebanoff C, Ji Y, Li P, Yu Z. et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 2016;23(1):63–76. doi:10.1016/j.cmet.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Liu X, Peng G. Mitochondria orchestrate T cell fate and function. Nat Immunol. 2021;22(3):276–278. doi:10.1038/s41590-020-00861-6.
   PubMed Web of Science ®Google Scholar
• Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM. Mitochondrial mass governs the extent of human T cell senescence. Aging Cell. 2020;19(2):e13067. doi:10.1111/acel.13067.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Oda SK, Bates BM, Burnett MG, Rodgers Suarez M, Ruskin SL, Greenberg PD. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. J Immunother Cancer. 2022;10(3). doi:10.1136/jitc-2021-003959.
   Web of Science ®Google Scholar
• Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015;22(4):549–559. doi:10.1038/cdd.2015.3.
   PubMed Web of Science ®Google Scholar
• Gao T, Huang J, Yin H, Huang J, Xie J, Zhou T, Fan W, Yang X, Gao G, Li Z. et al. Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell Death Disease. 2023;14(5):316. doi:10.1038/s41419-023-05833-w.
   PubMed Web of Science ®Google Scholar
• Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K, Matsuzaki J, Segal BH. et al. Predictive and prognostic implications of circulating CX3CR1+ CD8+ T cells in non–small cell lung cancer patients treated with chemo-immunotherapy. Cancer Res Commun. 2023;3(3):510–520. doi:10.1158/2767-9764.CRC-22-0383.
   PubMedGoogle Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature12213.
   PubMed Web of Science ®Google Scholar
• Zwijnenburg AJ, Pokharel J, Varnaitė R, Zheng W, Hoffer E, Shryki I, Comet NR, Ehrström M, Gredmark-Russ S, Eidsmo L. et al. Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. Immunity. 2023;56(8):1955–1974.e10. doi:10.1016/j.immuni.2023.06.025.
   PubMed Web of Science ®Google Scholar
• Kurmi K, Liang D, van de Ven R, Georgiev P, Gassaway BM, Han S, Notarangelo G, Harris IS, Yao C-H, Park JS. et al. Metabolic modulation of mitochondrial mass during CD4+ T cell activation. Cell Chem Biol. 2023;30(9):1064–1075.e8. doi:10.1016/j.chembiol.2023.08.008.
   PubMed Web of Science ®Google Scholar
• Nava Lauson CB, Tiberti S, Corsetto PA, Conte F, Tyagi P, Machwirth M, Ebert S, Loffreda A, Scheller L, Sheta D. et al. Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. Cell Metab. 2023;35(4):633–650.e9. doi:10.1016/j.cmet.2023.02.013.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T Cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374–388. doi:10.1016/j.immuni.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol. 2012;13(9):566–578. doi:10.1038/nrm3412.
   PubMed Web of Science ®Google Scholar
• Wenner CE. Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol. 2012;227(2):450–456. doi:10.1002/jcp.22788.
   PubMed Web of Science ®Google Scholar
• Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N. Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit Rev Immunol. 2014;34(4):301–314. doi:10.1615/CritRevImmunol.2014009988.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bárdos T, Mikecz K, Finnegan A, Glant TT. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol. 2001;166(8):4981–4986. doi:10.4049/jimmunol.166.8.4981.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sun R, Zhao H-J, Fu D, Zhong H-J, Weng X-Q, Qu B, Zhao Y, Wang L, Zhao W-L. et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer. 2019;18(1):54. doi:10.1186/s12943-019-0977-3.
   PubMed Web of Science ®Google Scholar